Zhan YN - Search Results

1

TGF-β1, in association with the increased expression of connective tissue growth factor, induce the hypertrophy of the ligamentum flavum through the p38 MAPK pathway.

Cao YL, Duan Y, Zhu LX, Zhan YN, Min SX, Jin AM. Cao YL, et al. Among authors: zhan yn. Int J Mol Med. 2016 Aug;38(2):391-8. doi: 10.3892/ijmm.2016.2631. Epub 2016 Jun 8. Int J Mol Med. 2016. PMID: 27279555 Free PMC article.

2

Integrative analysis of genome-wide DNA methylation and single-nucleotide polymorphism identified ACSM5 as a suppressor of lumbar ligamentum flavum hypertrophy.

Cao Y, Zhan Y, Qiu S, Chen Z, Gong K, Ni S, Duan Y. Cao Y, et al. Arthritis Res Ther. 2021 Sep 30;23(1):251. doi: 10.1186/s13075-021-02625-5. Arthritis Res Ther. 2021. PMID: 34593020 Free PMC article.

3

Volumetric changes in subcortical structures following repeated ketamine treatment in patients with major depressive disorder: a longitudinal analysis.

Zhou YL, Wu FC, Liu WJ, Zheng W, Wang CY, Zhan YN, Lan XF, Ning YP. Zhou YL, et al. Among authors: zhan yn. Transl Psychiatry. 2020 Aug 3;10(1):264. doi: 10.1038/s41398-020-00945-9. Transl Psychiatry. 2020. PMID: 32747631 Free PMC article.

4

A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression.

Zheng W, Zhou YL, Liu WJ, Wang CY, Zhan YN, Lan XF, Zhang B, Ning YP. Zheng W, et al. Among authors: zhan yn. J Affect Disord. 2020 Oct 1;275:38-43. doi: 10.1016/j.jad.2020.06.020. Epub 2020 Jun 25. J Affect Disord. 2020. PMID: 32658821

5

[Biochar addition improves soil phosphorus availability: A meta-analysis].

Zhan YN, Wang Z, Meng YL. Zhan YN, et al. Ying Yong Sheng Tai Xue Bao. 2020 Apr;31(4):1185-1193. doi: 10.13287/j.1001-9332.202004.024. Ying Yong Sheng Tai Xue Bao. 2020. PMID: 32530193 Chinese.

6

Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder.

Zheng W, Zhou YL, Liu WJ, Wang CY, Zhan YN, Li HQ, Chen LJ, Li MD, Ning YP. Zheng W, et al. Among authors: zhan yn. J Psychopharmacol. 2019 Apr;33(4):494-501. doi: 10.1177/0269881119827811. Epub 2019 Feb 21. J Psychopharmacol. 2019. PMID: 30789302 Clinical Trial.

7

Neurocognitive performance and repeated-dose intravenous ketamine in major depressive disorder.

Zheng W, Zhou YL, Liu WJ, Wang CY, Zhan YN, Li HQ, Chen LJ, Li MD, Ning YP. Zheng W, et al. Among authors: zhan yn. J Affect Disord. 2019 Mar 1;246:241-247. doi: 10.1016/j.jad.2018.12.005. Epub 2018 Dec 10. J Affect Disord. 2019. PMID: 30590286 Clinical Trial.

8

Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.

Zheng W, Zhou YL, Liu WJ, Wang CY, Zhan YN, Li HQ, Chen LJ, Li MD, Ning YP. Zheng W, et al. Among authors: zhan yn. J Psychiatr Res. 2018 Nov;106:61-68. doi: 10.1016/j.jpsychires.2018.09.013. Epub 2018 Sep 25. J Psychiatr Res. 2018. PMID: 30278319

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters